Pramiracetam is a nootropic drug [1].
Pramiracetam is investigated for its cognition-enhancing properties. A lower dosage of pramiracetam (100 mg/kg i.p.) was inadequate on NOS mRNA expression and chemical action. Interestingly, organization of pramiracetam (300 mg/kg i.p.) in rats pretreated (24 h before) with lithium chloride (LiCl) (3 mEq/kg i.p.) yielded a 40% expansion in cortical NOS action. Be that as it may, in LiCl-pretreated rats this nootropic neglected to influence cortical NOS mRNA expression; LiCl (3 mEq/kg i.p.) given alone delivered no impact. In summary, the present information show that pramiracetam given alone or in blend with LiCl builds NOS movement in mind cortical homogenates of rats and this might add to the components fundamental learning and memory change created by this nootropic. [1]
Antidementia viability of pramiracetam in 10 patients with likely Alzheimer's sickness was assessed utilizing a 2-phase, placebo-controlled, enhancement-type trial design. Eight patients prove a best dosage in the measurement finding stage, however in the ensuing replication stage just two again enhanced to a comparable degree. PETs with fluorodeoxyglucose got in two people demonstrated no distinct change. Dosages up to 4,000 mg pramiracetam are unrealistic to give symptomatic advantage to Alzheimer's infection patients. [2]
References:
Systemic administration of pramiracetam increases nitric oxide synthase activity in the cerebral cortex of the rat. Funct Neurol. 1995 May-Jun;10(3):151-5.
Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology. 1991 Apr;41(4):570-4.